Delivery of genes, including plasmid DNAs, short interfering RNAs (siRNAs), and
messenger RNAs (mRNAs), using artificial non-viral nanotherapeutics is a promising …

With the rapid development of biopharmaceuticals and the outbreak of COVID-19, the world
has ushered in a frenzy to develop gene therapy. Therefore, therapeutic genes have …

Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic
diversity. Various strategies are clinically available for diagnosis and treatment of lung …

RNA-based medicine is receiving growing attention for its diverse roles and potential
therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe …

Melittin (MEL) is a 26-amino acid polypeptide with a variety of pharmacological and
toxicological effects, which include strong surface activity on cell lipid membranes, hemolytic …

Background: Worldwide, lung cancer is one of the leading causes of cancer death.
Nevertheless, new therapeutic agents have been developed to treat lung cancer that could …

Carriers for RNA delivery must be dynamic, first stabilizing and protecting therapeutic RNA
during delivery to the target tissue and across cellular membrane barriers and then …

Internalizing therapeutic molecules or genes into cells and safely delivering them to the
target tissue where they can perform the intended tasks is one of the key characteristics of …

Acute viral respiratory tract infections (AVRIs) are a major burden on human health and
global economy and amongst the top five causes of death worldwide resulting in an …

Despite impressive recent establishment of therapeutic nucleic acids as drugs and vaccines,
their broader medical use is impaired by modest performance in intracellular delivery …